Boston Scientific Co. (NYSE:BSX) Shares Sold by Aristotle Atlantic Partners LLC

Aristotle Atlantic Partners LLC cut its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 6.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 226,184 shares of the medical equipment provider's stock after selling 14,358 shares during the period. Aristotle Atlantic Partners LLC's holdings in Boston Scientific were worth $20,203,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. TFC Financial Management Inc. raised its stake in Boston Scientific by 308.8% during the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 210 shares during the last quarter. West Oak Capital LLC acquired a new stake in shares of Boston Scientific during the 4th quarter worth approximately $29,000. Valley National Advisers Inc. grew its position in shares of Boston Scientific by 262.4% during the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock worth $35,000 after buying an additional 286 shares during the period. Fairway Wealth LLC acquired a new stake in Boston Scientific during the 4th quarter worth approximately $36,000. Finally, Global Trust Asset Management LLC grew its holdings in shares of Boston Scientific by 64.5% during the fourth quarter. Global Trust Asset Management LLC now owns 436 shares of the medical equipment provider's stock worth $39,000 after buying an additional 171 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Stifel Nicolaus upped their price target on shares of Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. Morgan Stanley boosted their price objective on Boston Scientific from $100.00 to $120.00 and gave the stock an "overweight" rating in a report on Thursday, February 6th. Truist Financial raised their price objective on shares of Boston Scientific from $113.00 to $117.00 and gave the company a "buy" rating in a research report on Thursday, April 24th. Barclays boosted their price objective on shares of Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Finally, StockNews.com upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, April 29th. Twenty-three investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $114.52.

Insider Buying and Selling

In other news, SVP Vance R. Brown sold 4,826 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $95.09, for a total value of $458,904.34. Following the completion of the transaction, the senior vice president now owns 36,193 shares of the company's stock, valued at approximately $3,441,592.37. This trade represents a 11.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP John Bradley Sorenson sold 4,572 shares of the stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $104.54, for a total value of $477,956.88. Following the completion of the sale, the executive vice president now directly owns 18,705 shares in the company, valued at $1,955,420.70. This represents a 19.64 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 307,025 shares of company stock worth $31,742,060. 0.50% of the stock is owned by insiders.

Boston Scientific Stock Performance

Shares of Boston Scientific stock traded down $0.02 on Tuesday, reaching $104.22. 5,174,388 shares of the stock were exchanged, compared to its average volume of 6,341,112. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. Boston Scientific Co. has a twelve month low of $71.88 and a twelve month high of $107.17. The business has a 50 day moving average price of $98.64 and a two-hundred day moving average price of $95.60. The firm has a market capitalization of $154.15 billion, a price-to-earnings ratio of 83.38, a PEG ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The firm had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. During the same period in the previous year, the company posted $0.56 earnings per share. The business's revenue was up 20.9% on a year-over-year basis. Analysts anticipate that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.